PDCD1 and diffuse large B-cell lymphoma: Various phase I/II studies of the PD-1 antibody pembrolizumab are still ongoing, either as a single agent or in combination with antibodies, small molecular inhibitors, immunotherapeutic vaccine, dendritic cell therapy, and CAR T cell treatment in participants with DLBCL.